At the Extraordinary General Meeting (EGM) convened earlier today in Stockholm, the following was resolved in accordance with the proposals by the Board of Directors.
Performance based, long-term share program for the CEO and transfer of own shares
The EGM approved the Board of Directors’ proposal regarding a performance based, long-term share program for the new CEO Geoffrey McDonough. The share program is based on an own investment in Sobi shares in the market and the allotment requires, among other things, the fulfilment of certain performance based targets related to the development of Sobi’s share price.
The EGM also resolved to extend the Board of Directors’ authorizations, granted by the Annual General Meeting 2011, to issue and repurchase C-shares to also cover the share program for the CEO. In addition, the EGM approved the Board of Directors’ proposal regarding transfer of own shares under the CEO share program in order to secure the company’s obligations under the program.
Revised guidelines for remuneration to senior management
The EGM further resolved to approve the Board of Directors’ proposal on guidelines for remuneration to management. Full details on each proposal adopted by the EGM can be downloaded from www.sobi.com.
For more information, contact:
Åsa Stenqvist, VP Communications and Investor Relations
Phone: +46 8 697 21 88
About Swedish Orphan Biovitrum (Sobi)
Sobi is a leading European specialty pharmaceutical company focused on providing and developing specialty pharmaceuticals for patients with rare diseases and significant medical needs. The portfolio comprises about 60 marketed products, as well as projects in late clinical phase. Key therapeutic areas are hematological diseases, autoimmune diseases, hereditary metabolic disorders and therapeutic oncology. In 2010 Sobi had revenues of SEK 1.9 billion and approximately 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. For more information please visit www.sobi.com
